4d Molecular Therapeutics In (FDMT) Smart Money Holdings (13F, Q2 2026)

FDMT ranks #3507 out of 37501 tracked stocks by institutional interest — one of the most closely watched names in our coverage.

162 institutions disclose a position in FDMT, but none treat it as a major bet — even Acuta Capital Partners, LLC, its most concentrated holder, allocates just 4.7% of its own portfolio to it.

BlackRock has added to its FDMT position for two straight quarters, increasing it by $30.0M to reach $60.5M today.

Two Sigma Investments, LP has trimmed its FDMT position for two straight quarters, cutting it by $1.6M while still holding $924.1K.

FDMT is up 1.7% today, and institutions have been net buyers of $151.1M this quarter — today's price move and the underlying institutional flow are pointing the same direction.

FDMT reported a net loss of $179.2M over the trailing twelve months.

• Not yet profitable — net loss of $179.2M over the trailing twelve months
• Revenue grew 278712.1% year over year
• Net income improved year over year, from -$196.1M to -$179.2M
• Operating cash flow was negative, using $109.1M in cash
• Current ratio of 9.39x — enough short-term assets to cover short-term liabilities
• Liabilities run 0.12x equity — within a conventional range